What Is Vasoactive Intestinal Peptide (VIP)?
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide first isolated from porcine intestine and later identified as a widely distributed signaling molecule throughout the central and peripheral nervous systems. Despite its name, which reflects its original discovery context in gut tissue, VIP’s research relevance extends well beyond gastrointestinal physiology into immunology, circadian biology, and neuro-immune signaling. It belongs to the secretin/glucagon peptide superfamily and shares structural homology with pituitary adenylate cyclase-activating polypeptide (PACAP), with which it shares receptor targets.
VIP signals through two G-protein-coupled receptors, VPAC1 and VPAC2, both of which couple primarily to Gs proteins and activate adenylate cyclase, elevating intracellular cyclic AMP (cAMP). This receptor pharmacology places VIP in a distinct signaling category from peptides acting through Gq-coupled or receptor tyrosine kinase pathways, and researchers studying cAMP-dependent cell signaling frequently use VIP as a reference ligand precisely because of its well-characterized, high-affinity VPAC receptor engagement.
Immune Modulation and VPAC Receptor Signaling
VIP has been extensively studied as an immunomodulatory neuropeptide, with VPAC1 and VPAC2 receptors identified on numerous immune cell populations including T lymphocytes, macrophages, and dendritic cells. In vitro research using isolated immune cell cultures has demonstrated that VIP signaling through VPAC1 shifts cytokine production toward a T-helper 2 (Th2) profile, increasing IL-4 and IL-10 while suppressing pro-inflammatory cytokines such as TNF-alpha and IL-12 in activated macrophage models. This has made VIP a frequently referenced compound in research examining neuro-immune crosstalk and the resolution phase of inflammatory responses.
Additional research has characterized VIP’s effect on dendritic cell maturation, with VIP-treated dendritic cells in culture showing reduced expression of co-stimulatory molecules (CD80, CD86) and altered antigen-presentation capacity, consistent with a tolerogenic phenotype. These findings have positioned VIP as a tool compound in studies of immune tolerance mechanisms and the neuroendocrine regulation of adaptive immunity, an area of growing interest given the density of VIP-producing neurons found in close proximity to lymphoid tissue.
Gut-Brain Axis Signaling Research
VIP is one of the most extensively characterized neuropeptides in gut-brain axis research due to its dense expression in enteric neurons of the myenteric and submucosal plexuses. In vitro and ex vivo gut tissue models have shown that VIP release from enteric neurons regulates smooth muscle relaxation, intestinal secretion, and local blood flow, functioning as a key non-adrenergic, non-cholinergic (NANC) inhibitory neurotransmitter in the enteric nervous system. This mechanistic role is distinct from, but complementary to, other gastrointestinal peptide research such as work on BPC-157 and gut epithelial protection, which focuses on cytoprotective and barrier-repair mechanisms rather than direct enteric neurotransmission.
Beyond the enteric nervous system itself, VIP is also studied as a signaling molecule connecting gut-derived signals to central nervous system function. Research has examined VIP-producing neurons in the suprachiasmatic nucleus (SCN) of the hypothalamus, where VIP plays a role in synchronizing circadian rhythms across the neuronal population of the central clock. This dual role, peripheral enteric signaling and central circadian synchronization, illustrates why VIP is frequently described in the literature as a bridging molecule across the gut-brain axis rather than a single-system neuropeptide.
VIP in Circadian Rhythm and Neuroendocrine Research
Within the suprachiasmatic nucleus, VIP-expressing neurons are considered essential for inter-neuronal synchronization of circadian oscillators. Research using VIP receptor knockout models and in vitro SCN explant cultures has demonstrated that loss of VIP/VPAC2 signaling desynchronizes individual neuronal clock cells, producing erratic or dampened circadian rhythm output at the tissue level even though individual cells retain autonomous oscillatory capacity. This body of work has established VIP as a critical paracrine coupling signal for coordinated circadian timekeeping, distinct from its immune and gastrointestinal roles.
VIP has also been examined in neuroendocrine research contexts related to prolactin secretion, where it functions as a prolactin-releasing factor via VPAC receptor signaling on lactotroph cells in pituitary cell culture models. This adds a further dimension to VIP’s multi-system signaling profile, reinforcing its utility as a research tool for laboratories examining cAMP-dependent GPCR signaling across diverse tissue and cell-type contexts, from enteric neurons to pituitary cells to circulating immune cells. Researchers building integrated neuroendocrine panels sometimes compare this cAMP-driven prolactin signaling against the HPG-axis mechanisms examined in our Gonadorelin and HPG axis review, since both illustrate distinct hypothalamic-pituitary signaling nodes.
Formats for Laboratory Research
Stackpure supplies VIP in three formats to accommodate different experimental protocols. The lyophilized VIP Peptide Vial is the standard format for cell culture and receptor-binding studies requiring precise reconstitution and controlled dosing into media. The VIP Pre-Mixed Peptide format offers a ready-to-use solution for laboratories that prefer to avoid a manual reconstitution step in time-sensitive protocols. The VIP Nasal Spray format is used in a smaller subset of research examining mucosal and intranasal delivery kinetics as a route-of-administration variable distinct from direct in vitro application.
Because VIP is subject to rapid enzymatic degradation by peptidases in biological matrices, similar to many short-chain neuropeptides, researchers should account for its relatively short functional half-life when designing time-course experiments, and should verify peptide integrity via COA prior to use in signaling assays where degraded peptide could confound dose-response interpretation.
Research Limitations and Considerations
VIP’s pleiotropic receptor distribution across the nervous, immune, and gastrointestinal systems is both a strength and a complicating factor for experimental design. Because VPAC1 and VPAC2 are broadly expressed, isolating a single mechanistic pathway in whole-tissue or in vivo models can be challenging without receptor-subtype-selective agonists or antagonists, or the use of knockout models to dissect specific contributions. Much of the immune modulation literature is derived from isolated cell culture systems, and translating these findings to intact organismal immune responses requires caution given the complexity of in vivo neuro-immune interactions.
As with all neuropeptides discussed on this site, VIP is not an approved therapeutic agent, and existing research does not establish safety or efficacy for any human application. All findings referenced here are drawn from in vitro, ex vivo, and animal research models and should be interpreted strictly within the bounds of the experimental systems in which they were generated.
Frequently Asked Questions
What receptors does VIP act on?
VIP signals through two G-protein-coupled receptors, VPAC1 and VPAC2, both coupled to Gs proteins and adenylate cyclase, elevating intracellular cAMP. It shares these receptors with the structurally related peptide PACAP.
How does VIP research differ from BPC-157 gut research?
VIP is studied primarily as an enteric neurotransmitter regulating smooth muscle tone, secretion, and gut-brain signaling via VPAC receptors. BPC-157 research instead focuses on cytoprotective mechanisms and epithelial barrier repair. The two peptides are mechanistically distinct but are sometimes studied together in integrated gastrointestinal research protocols.
What immune cells express VIP receptors?
VPAC1 and VPAC2 receptors have been identified on T lymphocytes, macrophages, and dendritic cells in in vitro immune cell culture models, where VIP signaling has been shown to shift cytokine profiles toward a Th2-skewed, anti-inflammatory pattern.
What formats does Stackpure offer for VIP research?
Stackpure offers VIP as a lyophilized peptide vial, a pre-mixed ready-to-use solution, and a nasal spray formulation for mucosal delivery research protocols.
Is VIP related to circadian rhythm research?
Yes. VIP-expressing neurons in the suprachiasmatic nucleus are considered essential for synchronizing circadian oscillators across the central clock, and VPAC2 receptor signaling has been shown in explant models to be necessary for coordinated tissue-level circadian output.
This article is provided for scientific and educational research purposes only. VIP (Vasoactive Intestinal Peptide) is sold by Stackpure strictly for in vitro laboratory research use. It is not intended for human consumption, therapeutic use, or dosing of any kind, and nothing in this article constitutes medical advice or a recommendation for use in humans or animals outside of a controlled research setting.